RxDoctor Payments Data

Marshal Blatt, MD

Psychiatry · Monterey, CANPI 1699882423

Payments from drug & device makers

$41,226in general payments, 2019–2025

Across 2,354 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$7K
  • Alkermes, Inc.$7K
  • AbbVie$5K
  • Sunovion Pharmaceuticals Inc.$3K
  • Johnson & Johnson$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • plus $15K from 29 others

What the payments were for

  • Consulting fees$5681%
  • Speaking & faculty fees$8,06320%
  • Food & beverage$32,22578%
  • Education$3701%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,226 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$107,812
Medicare patients
321
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine13$54,570
UzedyRisperidone16$52,904
RexultiBrexpiprazole21$51,033
Abilify MaintenaAripiprazole17$50,309
VraylarCariprazine Hcl13$25,140
SpravatoEsketamine Hcl18$20,663
CaplytaLumateperone Tosylate11$17,186
Aripiprazole215$9,789
TrintellixVortioxetine Hydrobromide12$6,695
BelsomraSuvorexant11$4,645
Clonazepam293$3,141
Bupropion XlBupropion Hcl153$3,093
Divalproex Sodium ErDivalproex Sodium73$3,028
Mirtazapine123$2,920
Quetiapine Fumarate79$2,889

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo, Uzedy$2,281$107,47429 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$7,355$101,34238 claims
AbbVieVraylar$4,506$25,14013 claims
Johnson & JohnsonSpravato$2,431$20,66318 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$1,825$17,18611 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$1,072$6,69512 claims
MerckBelsomra$589$4,64511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Monterey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →